trabectedin sarcoma
Selected indexed studies
- Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. (N Engl J Med, 2024) [PMID:39231341]
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. (Lancet Oncol, 2022) [PMID:35835135]
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. (J Clin Oncol, 2016) [PMID:26371143]
_Worker-drafted node — pending editorial review._
Connections
trabectedin sarcoma is a side effect of
Sources
- Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. (2022) pubmed
- Doxorubicin-Trabectedin with Trabectedin Maintenance in Leiomyosarcoma. (2024) pubmed
- Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial. (2016) pubmed
- Trabectedin as second-line treatment in advanced soft tissue sarcoma: quality of life and safety outcomes. (2022) pubmed
- Trabectedin and Eribulin: Where Do They Fit in the Management of Soft Tissue Sarcoma? (2017) pubmed
- Trabectedin for Soft Tissue Sarcoma: Current Status and Future Perspectives. (2016) pubmed
- Trabectedin for L-Type Sarcoma: A Retrospective Multicenter Study. (2024) pubmed
- A review of the efficacy of trabectedin as second-line treatment of advanced soft tissue sarcoma. (2022) pubmed
- Predicting Trabectedin Efficacy in Soft Tissue Sarcoma: Inflammatory Biomarker Analysis. (2024) pubmed
- Trabectedin for the treatment of advanced metastatic soft tissue sarcoma. (2010) pubmed